Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group (pages 22–29)Peter Grimm, Ignace Billiet, David Bostwick, Adam P. Dicker, Steven Frank, Jos Immerzeel, Mira Keyes, Patrick Kupelian, W. Robert Lee, Stefan Machtens, Jyoti Mayadev, Brian J. Moran, Gregory Merrick, Jeremy Millar, Mack Roach, Richard Stock, Katsuto Shinohara, Mark Scholz, Ed Weber, Anthony Zietman, Michael Zelefsky, Jason Wong, Stacy Wentworth, Robyn Vera and Stephen Langley
Article first published online: 12 JAN 2012 | DOI: 10.1111/j.1464-410X.2011.10827.x